MCID: OPP004
MIFTS: 43

Oppositional Defiant Disorder

Categories: Mental diseases

Aliases & Classifications for Oppositional Defiant Disorder

MalaCards integrated aliases for Oppositional Defiant Disorder:

Name: Oppositional Defiant Disorder 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050856
ICD10 33 F91.3

Summaries for Oppositional Defiant Disorder

MalaCards based summary : Oppositional Defiant Disorder is related to personality disorder and conduct disorder, and has symptoms including fatigue, sleep disturbances and photophobia. An important gene associated with Oppositional Defiant Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 72 Oppositional defiant disorder (ODD) is defined by the DSM-5 as \"a pattern of angry/irritable mood,... more...

Related Diseases for Oppositional Defiant Disorder

Diseases related to Oppositional Defiant Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
id Related Disease Score Top Affiliating Genes
1 personality disorder 27.2 COMT DRD2 DRD4 MAOA SLC6A2 SLC6A3
2 conduct disorder 10.7
3 attention deficit-hyperactivity disorder 10.7
4 multiple personality disorder 10.5 DRD4 MAOA
5 hypertrophy of breast 10.4 DRD4 SLC6A3
6 tubular variant testicular seminoma 10.4 SLC6A2 SLC6A3
7 conjunctival pigmentation 10.4 MAOA SLC6A4
8 anodontia 10.4 SLC6A3 SLC6A4
9 neurogenic bladder 10.4 MAOA SLC6A4
10 placenta disease 10.4 DRD2 DRD4
11 antisocial personality disorder 10.3 DRD2 DRD4
12 ring chromosome 14 syndrome 10.2 COMT MAOA
13 hyperthyroxinemia 10.2 DRD2 SLC6A4
14 pompholyx 10.2 DRD2 SLC6A4
15 anxiety disorder 10.2
16 acquired aneurysmal subarachnoid hemorrhage 10.2 MAOA SLC6A4
17 tinea pedis 10.1 MAOA SLC6A3 SLC6A4
18 amyloidosis, finnish type 10.1 COMT MAOA
19 myopathy, distal, with early respiratory failure, autosomal dominant 10.1 COMT SLC6A3
20 eosinophilia-myalgia syndrome 10.1 DRD2 DRD4 SLC6A3
21 rhinoscleroma 10.1 COMT DRD2
22 teebi kaurah syndrome 10.1 COMT DRD2
23 hepatic angiomyolipoma 10.0 SLC6A2 SLC6A3 SLC6A4
24 angiokeratoma of mibelli 10.0 MAOA SLC6A2 SLC6A4
25 autism spectrum disorder 10.0
26 hypoglycemic coma 10.0 MAOA SLC6A4
27 intracranial cavernous angioma 10.0 DRD2 SLC6A3 SLC6A4
28 splenic abscess 10.0 DRD2 SLC6A3 SLC6A4
29 hemopericardium 10.0 DBH DRD4
30 ulcerative colitis 10.0 COMT DRD2
31 suppurative periapical periodontitis 9.9 DRD2 SLC6A4
32 ornithosis 9.9 DRD2 MAOA SLC6A4
33 laryngeal adductor paralysis 9.9 DRD4 SLC6A4 TPH2
34 alcoholic liver cirrhosis 9.9 DRD2 DRD4 SLC6A4
35 asperger syndrome 9.9 DRD2 SLC6A3
36 pyogenic arthritis, pyoderma gangrenosum and acne 9.9 DBH MAOA
37 tic disorder 9.9
38 hematohidrosis 9.9
39 alcohol dependence 9.9
40 bipolar disorder 9.9
41 brain injury 9.9
42 traumatic brain injury 9.9
43 stuttering 9.9
44 separation anxiety disorder 9.9
45 borderline personality disorder 9.9
46 reading disorder 9.9
47 generalized anxiety disorder 9.9
48 uterus intravascular leiomyomatosis 9.8 COMT MAOA SLC6A4
49 brain meningioma 9.8 COMT DRD2
50 chronic dacryoadenitis 9.8 COMT MAOA SLC6A4

Graphical network of the top 20 diseases related to Oppositional Defiant Disorder:



Diseases related to Oppositional Defiant Disorder

Symptoms & Phenotypes for Oppositional Defiant Disorder

UMLS symptoms related to Oppositional Defiant Disorder:


fatigue, sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

MGI Mouse Phenotypes related to Oppositional Defiant Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 COMT DBH DRD2 DRD4 MAOA SLC6A2
2 homeostasis/metabolism MP:0005376 9.91 COMT DBH DRD2 DRD4 MAOA SLC6A2
3 cardiovascular system MP:0005385 9.87 COMT DBH DRD2 MAOA SLC6A2 SLC6A4
4 integument MP:0010771 9.63 DBH DRD2 SLC6A2 SLC6A3 SLC6A4 TPH2
5 nervous system MP:0003631 9.61 COMT DBH DRD2 DRD4 MAOA SLC6A2
6 taste/olfaction MP:0005394 8.8 DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Oppositional Defiant Disorder

Drugs for Oppositional Defiant Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158
3
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
4
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
5
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
6
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
7
Amphetamine Approved, Illicit Phase 4 300-62-9 5826 3007
8
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
9
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
10
Ziprasidone Approved Phase 4,Phase 2 146939-27-7 60854
11 Antipsychotic Agents Phase 4,Phase 3,Phase 2
12 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
13 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3
14 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Dopamine Antagonists Phase 4,Phase 3,Phase 2
16 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
19 Psychotropic Drugs Phase 4,Phase 3,Phase 2
20
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
21 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Serotonin Antagonists Phase 4,Phase 3,Phase 2
23 Tranquilizing Agents Phase 4,Phase 3,Phase 2
24 Adrenergic Agents Phase 4,Phase 3
25 Adrenergic Agonists Phase 4
26 Adrenergic alpha-2 Receptor Agonists Phase 4
27 Adrenergic alpha-Agonists Phase 4
28 Antihypertensive Agents Phase 4
29 Anticonvulsants Phase 4
30 Antimanic Agents Phase 4
31 GABA Agents Phase 4
32 Atomoxetine Hydrochloride Phase 4,Phase 3
33 Autonomic Agents Phase 4
34 Peripheral Nervous System Agents Phase 4
35 Antiemetics Phase 4
36 Gastrointestinal Agents Phase 4
37 insulin Phase 4
38 Insulin, Globin Zinc Phase 4
39 Serotonin Uptake Inhibitors Phase 4
40
Ethanol Approved Phase 2, Phase 3 64-17-5 702
41
2-Phenylethanol Experimental Phase 2, Phase 3 60-12-8 6054
42 Pharmaceutical Solutions Phase 3,Phase 2
43 Anti-Infective Agents Phase 2, Phase 3
44 Anti-Infective Agents, Local Phase 2, Phase 3
45 Disinfectants Phase 2, Phase 3
46
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
47 Quetiapine Fumarate Phase 2 111974-72-2
48 Oxytocics Phase 2
49 Brexpiprazole Approved Phase 1 913611-97-9 11978813
50 Dopamine agonists Phase 1

Interventional clinical trials:

(show top 50) (show all 55)

id Name Status NCT ID Phase Drugs
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
2 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Unknown status NCT02048241 Phase 4 Intuniv
3 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
4 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Completed NCT00406354 Phase 4 Atomoxetine;Placebo
5 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
6 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
7 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
8 Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD Recruiting NCT02638168 Phase 4 Immediate Release Methylphenidate;Placebo
9 Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder Recruiting NCT02951754 Phase 4 Immediate-release Methylphenidate
10 An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). Completed NCT00192023 Phase 3 atomoxetine 0.5 mg/kg/day;placebo;atomoxetine 1.2 mg/kg/day;atomoxetine 1.2-1.4 mg/kg/day
11 Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD Completed NCT00191698 Phase 3 atomoxetine hydrochloride;placebo
12 Treatment of Children With Peer Related Aggressive Behavior Completed NCT01406067 Phase 3
13 Strongest Families Ontario (Formerly the Family Help Program) Completed NCT01473511 Phase 3
14 A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation Completed NCT00266552 Phase 3 risperidone
15 A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Completed NCT00250354 Phase 3 Risperidone oral solution
16 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
17 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Completed NCT00922636 Phase 2, Phase 3 LY2216684;Methylphenidate;Placebo (tablet);Placebo (capsule)
18 Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders Completed NCT00402857 Phase 3
19 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Terminated NCT00965419 Phase 2, Phase 3 LY2216684
20 Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders Completed NCT00676429 Phase 2 Ziprasidone Hydrochloride;Placebo
21 Home Based Treatment for Drug Use in Early Adolescents Completed NCT00280228 Phase 2
22 Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior. Completed NCT00550147 Phase 2 Oros Methylphenidate;quetiapine
23 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
24 Treatment of Conduct Problems and Depression Unknown status NCT01267773 Phase 1
25 Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Not yet recruiting NCT03292848 Phase 1 Brexpiprazole
26 Prevention of Oppositional Defiant and Conduct Disorders in Preschool Children Unknown status NCT00189189
27 Guided Self-Help for Parents of Children With Externalizing Problem Behavior Unknown status NCT01350986
28 Explore the Association Between Neuropsychological Functions and ADHD Diagnosis and Comorbid Using Longitudinal Study in Preschool Children Unknown status NCT02433145
29 Toolkit for School Behavior Modification in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Unknown status NCT01330849
30 Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder Completed NCT00510120
31 Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth Completed NCT00404911
32 Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits Completed NCT01362946
33 On-line Treatment for Conduct Problems Completed NCT01822392
34 Supplements and Social Skills Intervention Study Completed NCT00819429
35 Resources to Enhance the Adjustment of Children (REACH) Completed NCT00820001
36 Evaluating the Feasibility of Internet-delivered PCIT Completed NCT03260725
37 The Effectiveness of Parent-Child Interaction Therapy (PCIT) Completed NCT01085305
38 School-Based Mental Health Services for Urban Children Completed NCT00612690
39 Brain Changes in Children and Adolescents With Behavioral Problems Completed NCT00104039
40 Correlating Real and Virtual World Behavioral Fluctuations in Adolescence Completed NCT02281825
41 Anger Control Training for Youth With Tourette Syndrome Completed NCT00486551
42 Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges Completed NCT02766101
43 Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) Completed NCT00579267
44 Parent Training and Emotion Coaching for Children With Limited Prosocial Emotions Recruiting NCT02409992
45 Treatment of Children With Peer Related Aggressive Behavior (ScouT) Recruiting NCT02143427
46 Epidemiological Study for Psychiatric Disorder Among Children and Adolescents Recruiting NCT02707848
47 Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents Recruiting NCT02485587
48 Psychological Treatments for Youth With Severe Irritability. Recruiting NCT02531893
49 Child and Family Outcomes and Consumer Satisfaction for Online vs Staff-Delivered Parenting Intervention Recruiting NCT02121431
50 Family Groups for Urban Youth With Disruptive Behavior Recruiting NCT02715414

Search NIH Clinical Center for Oppositional Defiant Disorder

Genetic Tests for Oppositional Defiant Disorder

Anatomical Context for Oppositional Defiant Disorder

MalaCards organs/tissues related to Oppositional Defiant Disorder:

39
Brain, Testes, Eye, Cortex

Publications for Oppositional Defiant Disorder

Articles related to Oppositional Defiant Disorder:

(show top 50) (show all 133)
id Title Authors Year
1
Oppositional defiant disorder dimensions: genetic influences and risk for later psychopathology. ( 28059443 )
2017
2
Age 4 Predictors of Oppositional Defiant Disorder in Early Grammar School. ( 28278601 )
2017
3
The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder. ( 28398816 )
2017
4
Structural Brain Abnormalities of Attention-Deficit/Hyperactivity Disorder With Oppositional Defiant Disorder. ( 28911901 )
2017
5
Multi-Level Family Factors and Affective and Behavioral Symptoms of Oppositional Defiant Disorder in Chinese Children. ( 28713321 )
2017
6
Parental involvement as an etiological moderator of middle childhood oppositional defiant disorder. ( 28263622 )
2017
7
Sex differences in the associations between vagal reactivity and oppositional defiant disorder symptoms. ( 28573761 )
2017
8
Boys with Oppositional Defiant Disorder/Conduct Disorder Show Impaired Adaptation During Stress: An Executive Functioning Study. ( 28755013 )
2017
9
Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( 28225747 )
2017
10
Neurobiological stress responses predict aggression in boys with oppositional defiant disorder/conduct disorder: a 1-year follow-up intervention study. ( 28181041 )
2017
11
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( 28806385 )
2017
12
Testing Multiple Conceptualizations of Oppositional Defiant Disorder in Youth. ( 28287828 )
2017
13
Family and Individual Risk and Protective Factors of Depression among Chinese Migrant Children with Oppositional Defiant Disorder Symptoms. ( 28421024 )
2017
14
Is emotional dysregulation a risk indicator for auto-aggression behaviors in adolescents with oppositional defiant disorder? ( 27764737 )
2017
15
Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial. ( 28213188 )
2017
16
Risk factors for comorbid oppositional defiant disorder in attention-deficit/hyperactivity disorder. ( 28283834 )
2017
17
Innocent or Intentional?: Interpreting Oppositional Defiant Disorder in a Preschool Mental Health Clinic. ( 27761690 )
2016
18
Child Personality Accounts for Oppositional Defiant Disorder Comorbidity Patterns. ( 27233508 )
2016
19
Perceived Parent-Child Relations, Conduct Problems, and Clinical Improvement Following the Treatment of Oppositional Defiant Disorder. ( 27284234 )
2016
20
Common Questions About Oppositional Defiant Disorder. ( 27035043 )
2016
21
A Systematic Review and Meta-analysis of Neuroimaging in Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) Taking Attention-Deficit Hyperactivity Disorder (ADHD) Into Account. ( 26846227 )
2016
22
Memory consolidation of socially relevant stimuli during sleep in healthy children and children with attention-deficit/hyperactivity disorder and oppositional defiant disorder: What you can see in their eyes. ( 28049026 )
2016
23
Sex Differences in the Prevalence of Oppositional Defiant Disorder During Middle Childhood: a Meta-Analysis. ( 27282758 )
2016
24
Early development of comorbidity between symptoms of attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD). ( 26854502 )
2016
25
Emotion Regulation Difficulties in Boys with Oppositional Defiant Disorder/Conduct Disorder and the Relation with Comorbid Autism Traits and Attention Deficit Traits. ( 27420110 )
2016
26
Oral health status, dental anxiety, and behavior-management problems in children with oppositional defiant disorder. ( 26707341 )
2016
27
Maltreatment and Emotional and Behavioral Problems in Chinese Children With and Without Oppositional Defiant Disorder: The Mediating Role of the Parent-Child Relationship. ( 26811315 )
2016
28
Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children. ( 27443598 )
2016
29
Emotional Regulation and Executive Function Deficits in Unmedicated Chinese Children with Oppositional Defiant Disorder. ( 27247593 )
2016
30
Association of tryptophan hydroxylase-2 polymorphisms with oppositional defiant disorder in a Chinese Han population. ( 27871272 )
2016
31
Trait and State Variance in Oppositional Defiant Disorder Symptoms: A Multi-Source Investigation With Spanish Children. ( 27148784 )
2016
32
Emotion Socialization in the Context of Risk and Psychopathology: Maternal Emotion Coaching Predicts Better Treatment Outcomes for Emotionally Labile Children with Oppositional Defiant Disorder. ( 26848211 )
2016
33
Is Emotional Lability Distinct From "Angry/Irritable Mood," "Negative Affect," or Other Subdimensions of Oppositional Defiant Disorder in Children With ADHD? ( 26842831 )
2016
34
Emotional Abilities in Children with Oppositional Defiant Disorder (ODD): Impairments in Perspective-Taking and Understanding Mixed Emotions are Associated with High Callous-Unemotional Traits. ( 27100725 )
2016
35
Factors related to the comorbidity between oppositional defiant disorder and anxiety disorders in preschool children. ( 27575516 )
2016
36
Callous unemotional traits, autism spectrum disorder symptoms and empathy in boys with oppositional defiant disorder or conduct disorder. ( 27575651 )
2016
37
Predicting Depression and Anxiety from Oppositional Defiant Disorder Symptoms in Elementary School-Age Girls and Boys with Conduct Problems. ( 27209374 )
2016
38
The Longitudinal Effects of Oppositional Defiant Disorder Symptoms on Academic and Occupational Functioning in the Transition to Young Adulthood. ( 27469319 )
2016
39
Preschool Oppositional Defiant Disorder: A Disorder of Negative Affect, Surgency, and Disagreeableness. ( 27768388 )
2016
40
Multiple Levels of Family Factors and Oppositional Defiant Disorder Symptoms Among Chinese Children. ( 27900762 )
2016
41
The role of anxiety in cortisol stress response and cortisol recovery in boys with oppositional defiant disorder/conduct disorder. ( 27521740 )
2016
42
The Reciprocal Influence of Callous-Unemotional Traits, Oppositional Defiant Disorder and Parenting Practices in Preschoolers. ( 27013514 )
2016
43
The Pharmacological Management of Oppositional Behaviour, Conduct Problems, and Aggression in Children and Adolescents With Attention-Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, and Conduct Disorder: A Systematic Review and Meta-Analysis. Part 1: Psychostimulants, Alpha-2 Agonists, and Atomoxetine. ( 25886655 )
2015
44
Pharmacological Management of Pediatric Patients with Comorbid Attention-Deficit Hyperactivity Disorder Oppositional Defiant Disorder. ( 26233632 )
2015
45
Trajectories of Oppositional Defiant Disorder Irritability Symptoms in Preschool Children. ( 25630822 )
2015
46
Beyond Symptom Counts for Diagnosing Oppositional Defiant Disorder and Conduct Disorder? ( 25788042 )
2015
47
Neurocognitive Deficits in Attention-Deficit/Hyperactivity Disorder With and Without Comorbid Oppositional Defiant Disorder. ( 26486602 )
2015
48
Clinical Characteristics of Preschool Children with Oppositional Defiant Disorder and Callous-Unemotional Traits. ( 26418062 )
2015
49
Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. ( 26097819 )
2015
50
Callous-unemotional traits in a child with attention-deficit/hyperactivity disorder and oppositional defiant disorder: managing medication and expectations. ( 25885014 )
2015

Variations for Oppositional Defiant Disorder

Expression for Oppositional Defiant Disorder

Search GEO for disease gene expression data for Oppositional Defiant Disorder.

Pathways for Oppositional Defiant Disorder

Pathways related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 COMT MAOA SLC6A3 SLC6A4
2
Show member pathways
12.39 COMT DRD2 DRD4 MAOA SLC6A3
3 12.25 COMT DBH TPH2
5 11.91 MAOA SLC6A4 TPH2
6 11.85 SLC6A2 SLC6A3 SLC6A4
7
Show member pathways
11.7 DRD2 MAOA SLC6A3
8 11.66 MAOA SLC6A4 TPH2
9
Show member pathways
11.46 COMT DBH MAOA
10
Show member pathways
11.16 DBH TPH2
11 10.9 DBH SLC6A2
12 10.88 MAOA SLC6A4 TPH2
13
Show member pathways
10.73 DBH MAOA SLC6A2 SLC6A3 SLC6A4 TPH2
14
Show member pathways
10.69 COMT MAOA SLC6A3 SLC6A4
15
Show member pathways
10.67 COMT DBH MAOA
16 10.64 COMT MAOA
17
Show member pathways
10.62 COMT MAOA

GO Terms for Oppositional Defiant Disorder

Cellular components related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.76 COMT DBH DRD2 DRD4 MAOA SLC6A2
2 integral component of plasma membrane GO:0005887 9.65 DRD2 DRD4 SLC6A2 SLC6A3 SLC6A4
3 axon GO:0030424 9.5 COMT DRD2 SLC6A3
4 membrane raft GO:0045121 9.13 SLC6A2 SLC6A3 SLC6A4
5 neuron projection GO:0043005 8.92 SLC6A2 SLC6A3 SLC6A4 TPH2

Biological processes related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 34)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.8 COMT DRD2 SLC6A2 SLC6A3 SLC6A4
2 locomotory behavior GO:0007626 9.7 DBH DRD2 SLC6A3
3 neurotransmitter transport GO:0006836 9.69 SLC6A2 SLC6A3 SLC6A4
4 social behavior GO:0035176 9.66 DRD4 SLC6A4
5 visual learning GO:0008542 9.66 DBH DRD2
6 response to nicotine GO:0035094 9.65 DRD2 SLC6A3
7 response to cocaine GO:0042220 9.65 DRD2 SLC6A3
8 positive regulation of multicellular organism growth GO:0040018 9.65 DRD2 SLC6A3
9 negative regulation of adenylate cyclase activity GO:0007194 9.64 DRD2 DRD4
10 associative learning GO:0008306 9.64 DBH DRD2
11 arachidonic acid secretion GO:0050482 9.63 DRD2 DRD4
12 behavioral response to cocaine GO:0048148 9.63 DRD2 DRD4
13 dopamine receptor signaling pathway GO:0007212 9.62 DRD2 DRD4
14 response to iron ion GO:0010039 9.62 DRD2 SLC6A3
15 negative regulation of protein secretion GO:0050709 9.61 DRD2 DRD4
16 neurotransmitter biosynthetic process GO:0042136 9.61 SLC6A3 SLC6A4
17 response to amphetamine GO:0001975 9.61 DBH DRD2 DRD4
18 negative regulation of voltage-gated calcium channel activity GO:1901386 9.6 DRD2 DRD4
19 ammonium transmembrane transport GO:0072488 9.59 SLC6A3 SLC6A4
20 prepulse inhibition GO:0060134 9.58 DRD2 SLC6A3
21 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 DRD4
22 neurotransmitter catabolic process GO:0042135 9.57 COMT MAOA
23 catecholamine metabolic process GO:0006584 9.56 COMT MAOA
24 regulation of dopamine metabolic process GO:0042053 9.55 DRD4 SLC6A3
25 adenohypophysis development GO:0021984 9.54 DRD2 SLC6A3
26 response to pain GO:0048265 9.54 COMT DBH SLC6A2
27 behavioral response to ethanol GO:0048149 9.5 DBH DRD2 DRD4
28 fear response GO:0042596 9.49 DBH DRD4
29 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD2 DRD4
30 response to histamine GO:0034776 9.46 DRD2 DRD4
31 dopamine metabolic process GO:0042417 9.43 COMT DRD2 DRD4
32 monoamine transport GO:0015844 9.33 SLC6A2 SLC6A3 SLC6A4
33 dopamine uptake involved in synaptic transmission GO:0051583 9.13 SLC6A2 SLC6A3 SLC6A4
34 dopamine catabolic process GO:0042420 8.92 COMT DBH MAOA SLC6A3

Molecular functions related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 symporter activity GO:0015293 9.58 SLC6A2 SLC6A3 SLC6A4
2 drug binding GO:0008144 9.5 DRD2 DRD4 SLC6A3
3 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A3 SLC6A4
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD2 DRD4
5 dopamine binding GO:0035240 9.33 DRD2 DRD4 SLC6A3
6 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD2 DRD4
7 monoamine transmembrane transporter activity GO:0008504 9.13 SLC6A2 SLC6A3 SLC6A4
8 dopamine:sodium symporter activity GO:0005330 8.8 SLC6A2 SLC6A3 SLC6A4

Sources for Oppositional Defiant Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....